EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetic/Pharmacodynamic Analysis of Quinidine‐Induced Dominant Frequency Reduction in Thoroughbred Horses With Atrial Fibrillation

Taisuke Kuroda iD, Yohei Minamijima iD, Yuji Takahashi iD, Yusaku Ebisuda iD, Kaori Yoshida, Hiroshi Ishikawa iD, Kei-Ichi Ishihara, Hiroshi Mita, Motoi Nomura iD, Toshio Nukada, Yuhiro Ishikawa

Journal of Veterinary Pharmacology and Therapeutics · 13.08.2026

DOI: 10.1111/jvp.70103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, online erschienen am 13.08.2026. Verfasst von Taisuke Kuroda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Veterinary Medicine Division, Equine Research Institute, Japan Racing Association, Shimotsuke, Japan. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Quinidine has long been used for the pharmacological treatment of atrial fibrillation (AF) in horses; however, the plasma concentration required for conversion to sinus rhythm remains unclear. Dominant frequency (DF), derived from surface electrocardiograms, reflects atrial activation rate during AF. This study aimed to quantify the relationship between plasma quinidine concentration and DF using a pharmacokinetic/pharmacodynamic (PK/PD) approach. Ten Thoroughbred horses with naturally occurring AF received quinidine sulfate via a nasogastric tube. Plasma quinidine concentrations and DF values, calculated from digitized atrial fibrillatory segments, were measured during treatment. PK/PD was analyzed using a sigmoid inhibitory E max model, with typical parameters including a baseline DF of 6.27 Hz, a maximal DF reduction of 3.63 Hz, a theoretical minimum DF of 2.64 Hz, an EC 50 of 0.78 μg/mL, and a Hill coefficient of 1.81. Nine horses converted to sinus rhythm, with median DF decreasing from 6.4 Hz to 3.0 Hz immediately before conversion. Model simulations indicated a pharmacodynamic plateau, with an increase in plasma quinidine concentration from 4 to 5 μg/mL resulting in only a 0.06‐Hz reduction in DF. A model‐predicted plasma quinidine concentration of 2.6 μg/mL achieved a DF of 3.0 Hz and may represent a target concentration for conversion.

Schlagwörter

Stichwörter der Autor:innen

atrial fibrillationdominant frequencypharmacodynamicspharmacokineticsquinidine

Autor:innen und Institutionen

  • Clinical Veterinary Medicine Division, Equine Research Institute, Japan Racing Association, Shimotsuke, Japan.
  • Graduate School of Agriculture, Tokyo University of Agriculture and Technology, Fuchu, Japan.
  • Drug Analysis Department, Laboratory of Racing Chemistry, Utsunomiya, Japan.
  • Sports Science Division, Equine Research Institute, Japan Racing Association, Shimotsuke, Japan.
  • Ritto-Training Center Racehorse Hospital, Japan Racing Association, Ritto, Japan.

ORCID-Profile: Taisuke Kuroda, Yohei Minamijima, Yuji Takahashi, Yusaku Ebisuda, Hiroshi Ishikawa, Motoi Nomura

Zitieren

APA

Kuroda, T., Minamijima, Y., Takahashi, Y., Ebisuda, Y., Yoshida, K., Ishikawa, H., Ishihara, K. I., Mita, H., Nomura, M., Nukada, T., & Ishikawa, Y. (2026). Pharmacokinetic/Pharmacodynamic Analysis of Quinidine‐Induced Dominant Frequency Reduction in Thoroughbred Horses With Atrial Fibrillation. Journal of Veterinary Pharmacology and Therapeutics. https://doi.org/10.1111/jvp.70103

Vancouver

Kuroda T, Minamijima Y, Takahashi Y, Ebisuda Y, Yoshida K, Ishikawa H, et al. Pharmacokinetic/Pharmacodynamic Analysis of Quinidine‐Induced Dominant Frequency Reduction in Thoroughbred Horses With Atrial Fibrillation. Journal of Veterinary Pharmacology and Therapeutics. 2026. doi:10.1111/jvp.70103

BibTeX
@article{Kuroda2026,
  author = {Kuroda, Taisuke and Minamijima, Yohei and Takahashi, Yuji and Ebisuda, Yusaku and Yoshida, Kaori and Ishikawa, Hiroshi and Ishihara, Kei-Ichi and Mita, Hiroshi and Nomura, Motoi and Nukada, Toshio and Ishikawa, Yuhiro},
  title = {Pharmacokinetic/Pharmacodynamic Analysis of Quinidine‐Induced Dominant Frequency Reduction in Thoroughbred Horses With Atrial Fibrillation},
  journal = {Journal of Veterinary Pharmacology and Therapeutics},
  year = {2026},
  doi = {10.1111/jvp.70103}
}
Kostenlos starten →